Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Endometrial Cancer: From Pathogenesis, Pathology Diagnosis and Molecular...
share announcement

Advances in Endometrial Cancer: From Pathogenesis, Pathology Diagnosis and Molecular Classification to Targeted Therapy

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 8953

Special Issue Editor

Prof. Dr. Wenxin Zheng

E-Mail Website
Guest Editor
Departments of Pathology, Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Interests: endometrial serous carcinogenesis; endometrial cancer pathogenesis; TCGA-endometrial cancer molecular classification; targeted therapy; immune therapy; uterine sarcoma; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endometrial cancer is the most common gynecologic malignancy and the fourth most common malignancy among women in the United States. The incidence of endometrial cancer continues to rise as the life expectancy of women increases. This Special Issue focuses on recent developments in the pathogenesis, molecular diagnosis and treatment of all histologic types of endometrial cancer.

This Special Issue will cover reports of clinically oriented pathogenesis-associated research findings, the impact of TCGA molecular classification in guidance on prognosis, the pros and cons of adjuvant therapies, preclinical data and clinical trials of targeted as well as immune therapies, and the development of novel treatment strategies. Research in formats including original research, reviews and commentary reviews are welcome. This Special Issue is expected to provide the most updated therapeutic-related advances and possible future directions in endometrial cancer.

Prof. Wenxin Zheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • endometrial carcinoma
  • uterine cancer
  • uterine sarcoma
  • TCGA molecular classification
  • endometrial cancer pathology
  • endometrial cancer pathogenesis
  • chemotherapy
  • radiotherapy
  • chemoradiotherapy
  • PORTEC studies
  • immunotherapy
  • targeted therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

15 pages, 4057 KiB  
Commentary
Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists
by Wenxin Zheng
Cancers 2023, 15(16), 4101; https://doi.org/10.3390/cancers15164101 - 15 Aug 2023
Cited by 11 | Viewed by 6833
Abstract
This commentary explores the complexities of the FIGO 2023 staging system and the inclusion of The Cancer Genome Atlas’s (TCGA) molecular classification in the management of endometrial cancer. It highlights the importance of histology as a prognostic tool, while scrutinizing the merits and [...] Read more.
This commentary explores the complexities of the FIGO 2023 staging system and the inclusion of The Cancer Genome Atlas’s (TCGA) molecular classification in the management of endometrial cancer. It highlights the importance of histology as a prognostic tool, while scrutinizing the merits and demerits of its application to aggressive endometrial cancers. The commentary review sheds light on the recent introductions of lymphovascular space invasion (LVSI) and lymph node metastasis size in cancer staging. It outlines the difficulties in differentiating between synchronous and metastatic endometrial and ovarian cancers, underlining their implications on treatment strategies. Furthermore, the commentary discusses the integration of molecular classifications within the FIGO 2023 framework, emphasizing the pivotal yet challenging implementation of the pathogenic POLE mutation test. The commentary concludes by reaffirming the vital role of pathologists in executing the FIGO 2023 staging system. Full article
(This article belongs to the Special Issue Advances in Endometrial Cancer: From Pathogenesis, Pathology Diagnosis and Molecular Classification to Targeted Therapy)
►▼ Show Figures

Figure 1

4 pages, 819 KiB  
Commentary
Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer
by Setsuko K. Chambers
Cancers 2022, 14(20), 5020; https://doi.org/10.3390/cancers14205020 - 14 Oct 2022
Cited by 3 | Viewed by 1494
Abstract
Endometrial cancer is now recognized to be several diseases with differing biology and responses to treatment. Improved molecular characterization has furthered the development and testing of targeted therapies in the different cohorts of endometrial cancer. Lessons are being learned from other cancers that [...] Read more.
Endometrial cancer is now recognized to be several diseases with differing biology and responses to treatment. Improved molecular characterization has furthered the development and testing of targeted therapies in the different cohorts of endometrial cancer. Lessons are being learned from other cancers that share similar molecular typing, and hence, potentially similar tumor behavior. This commentary serves as a broad overview of the types of advances to which our patients now have access. Full article
(This article belongs to the Special Issue Advances in Endometrial Cancer: From Pathogenesis, Pathology Diagnosis and Molecular Classification to Targeted Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop